UPDATE: Immunic Inc. (IMUX) Announces Positive Top-Line Data from Phase 2 EMPhASIS Trial of IMU-838 in Patients with Relapsing-Remitting MS

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. PRIM
2. ABBV
3. META
4. DPZ
5. IBM
6. CNC
7. KFY
8. SPY
9. MU
10. ENRD

Go back to UPDATE: Immunic Inc. (IMUX) Announces Positive Top-Line Data from Phase 2 EMPhASIS Trial of IMU-838 in Patients with Relapsing-Remitting MS

Immunic, Inc. Reports Positive Top-line Data from Phase 2 EMPhASIS Trial of IMU-838 in Patients with Relapsing-Remitting Multiple Sclerosis

August 2, 2020 3:00 PM EDT

NEW YORK, Aug. 2, 2020 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune diseases, today announced positive top-line data from its phase 2 EMPhASIS trial of lead... More